<DOC>
	<DOCNO>NCT03068468</DOCNO>
	<brief_summary>The purpose study determine efficacy safety intravenously administer BMS-986168 participant Progressive Supranuclear Palsy .</brief_summary>
	<brief_title>Study BMS-986168 Patients With Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>Participants probable possible PSP Able ambulate independently assistance Able tolerate MRI Have reliable caregiver accompany participant study visit Score great equal 20 Mini Mental State Exam ( MMSE ) screen Participant must reside outside skilled nursing facility dementia care facility time screen admission facility must plan Presence significant neurological psychiatric disorder Diagnosis amyotrophic lateral sclerosis ( ALS ) motor neuron disease History early , prominent rapid eye movement ( REM ) sleep behavior disorder History screen brain MRI scan indicative significant abnormality Known history serum plasma progranulin level le one standard deviation normal patient mean laboratory perform assay Other protocol define inclusion/exclusion criterion could apply .</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>